title: [Efficacy of erythromycin inhalation in chronic respiratory infection caused by Pseudomonas aeruginosa].
abstract: The prognosis of chronic respiratory tract infection with Pseudomonas aeruginosad considered to be poor. However, low-dose and long-term 14 membered macrolide, such as erythromycin or clarithromycin, treatment has been reported as effective clinically in chronic lower respiratory tract disease. There was no report to investigate the effect of macrolide on chronic biofilm related Pseudomonas aeruginosa respiratory tract infection in vivo. In a newly established murine model of chronic Pseudomonas aeruginosa respiratory infection mimicking diffuse panbronchiolitis (DPB), we investigated the effect of erythromcin inhalation on viable bacteria in the lungs. Infection was produced by placement of a plastic tube in the bronchus with inoculating. Pseudomonas aeruginosa suspended in saline was also inoculated in bronchus after intubation of the tube. Viable bacteria were constantly isolated at 10(4) 10(6) cfu-specimen from the lungs for more than 30 days. Treatment with erythromycin inhalation for four days reduced the number of viable bacteria in the lungs with statistically significant. Our result indicated that our new model of chronic respiratory tract infection is simple and provides a useful tool to study the pathogenic process and treatment of such infection. Our results also suggest that the erythromycin inhalation is effective on chronic Pseudomons aeruginosa respiratory infection.
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yanagihara
authors.forename: K
authors.initials: K
authors.lastname: Tomono
authors.forename: T
authors.initials: T
authors.lastname: Sawai
authors.forename: E
authors.initials: E
authors.lastname: Sasaki
authors.forename: H
authors.initials: H
authors.lastname: Kakeya
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: H
authors.initials: H
authors.lastname: Ohno
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: J
authors.initials: J
authors.lastname: Kadota
authors.forename: H
authors.initials: H
authors.lastname: Koga
authors.forename: S
authors.initials: S
authors.lastname: Kohno
authors.forename: Y
authors.initials: Y
authors.lastname: Hirakata
authors.forename: T
authors.initials: T
authors.lastname: Tashiro
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D018441:Biofilms / Q000254:growth & development*; D002908:Chronic Disease; D004917:Erythromycin / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000502:physiology*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D004917:Erythromycin